Clinical Trials Browser

Phase 2 × belzutifan × 1 year × Clear all

NCT04924075 2026-02-24

MK-6482-015

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

NCT07187778 2026-01-05

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Phase 2 Recruiting

Carcinoma, Renal Cell

NCT06428396 2025-12-26

LITESPARK-029

Phase 2 Recruiting

Breast Neoplasms

NCT06677190 2025-11-05

Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

Phase 2 Recruiting

Uterine Cervical Neoplasms, Ovarian Neoplasms, Uterine Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms, Endometrial Neoplasms

NCT07167329 2025-09-11

BELIEVE-VHL

Phase 2 Recruiting

CNSEndocrineGenitourinary

Carcinoma, Renal Cell, von Hippel-Lindau Disease, Paraganglioma, Pheochromocytoma, Neuroectodermal Tumors, Primitive, Hemangioblastoma

NCT07023432 2025-06-17

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Phase 2 Not yet recruiting

Carcinoma, Renal Cell

NCT04976634 2025-04-06

MK-6482-016

Phase 2 Active not recruiting

Neoplasms